Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Type / Class: Equity / Common Stock, par value $0.0001
Symbol: ACET on Nasdaq
Shares outstanding: 153,881,229
Price per share: $0.52
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares: 51,335,037
Total reported value: $41,591,047
% of total 13F portfolios: 0%
Share change: -268,034
Value change: -$36,562
Number of holders: 53
Price from insider filings: $0.52

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
ORBIMED ADVISORS LLC	9.6%		$11,974,668		14,772,598		ORBIMED ADVISORS LLC	08 Oct 2025
TANG CAPITAL MANAGEMENT LLC	9.9%		$6,208,827		8,223,612		TANG CAPITAL MANAGEMENT, LLC	31 Mar 2025

As of 30 Sep 2025, 53 institutional investors reported holding 51,335,037 shares of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET). This represents 33% of the company’s total 153,881,229 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) together control 33% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution	Ownership %	Shares Held	Share Change %	Portfolio %	Holdings Value
ORBIMED ADVISORS LLC	7.4%	11,447,140	0%	0.22%	$9,274,473
TANG CAPITAL MANAGEMENT LLC	5.3%	8,223,612	0%	0.26%	$6,662,770
RA CAPITAL MANAGEMENT, L.P.	4.9%	7,541,000	0%	0.08%	$6,109,718
GOLDMAN SACHS GROUP INC	2.4%	3,751,617	-0.01%	0%	$3,039,560
VANGUARD GROUP INC	2.1%	3,272,522	0%	0%	$2,650,743
Carlyle Group Inc.	1.9%	2,948,718	0%	0.06%	$2,388,756
ACADIAN ASSET MANAGEMENT LLC	1.5%	2,265,491	+9.2%	0%	$1,835,000
RENAISSANCE TECHNOLOGIES LLC	1.2%	1,828,949	+59%	0%	$1,481,814
REGENERON PHARMACEUTICALS, INC.	0.63%	968,183	0%	0.11%	$784,422
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.59%	901,600	0%	0.02%	$730,476
TWO SIGMA INVESTMENTS, LP	0.56%	854,568	+67%	0%	$692,371
TWO SIGMA ADVISERS, LP	0.51%	780,982	+38%	0%	$632,752
GEODE CAPITAL MANAGEMENT, LLC	0.46%	706,334	0%	0%	$572,440
Alyeska Investment Group, L.P.	0.43%	655,665	0%	0%	$531,220
RBF Capital, LLC	0.4%	617,319	0%	0.02%	$500,152
BlackRock, Inc.	0.38%	585,377	-2.4%	0%	$474,272
CITADEL ADVISORS LLC	0.38%	583,948	+27%	0%	$473,115
MILLENNIUM MANAGEMENT LLC	0.37%	565,953	-4.5%	0%	$458,535
Schonfeld Strategic Advisors LLC	0.31%	479,108	-75%	0%	$388,171
JOHNSON & JOHNSON	0.24%	364,472	0%	0.06%	$295,295
WEALTHEDGE INVESTMENT ADVISORS, LLC	0.19%	300,054	-4.2%	0.09%	$243,104
BARCLAYS PLC	0.19%	300,000	+100%	0%	$243,060
STATE STREET CORP	0.16%	244,186	-1.1%	0%	$197,840
JANE STREET GROUP, LLC	0.12%	186,200		0%	$150,859
NORTHERN TRUST CORP	0.09%	140,373	0%	0%	$113,730

Institutional Holders of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q4	0	$0	-$31,083			$0.52	0
2025 Q3	51,335,037	$41,591,047	-$36,562		$0	$0.81	53
2025 Q2	51,603,071	$31,484,026	-$3,114,241	$0	$16,592	$0.61	47
2025 Q1	55,856,035	$42,041,103	-$1,434,574	$12,458	$27,860	$0.76	56
2024 Q4	57,616,208	$55,430,722	-$199,853	$37,785	$7,023	$0.96	61
2024 Q3	56,696,706	$81,640,904	-$9,041,121	$9,648	$6,048	$1.44	61
2024 Q2	63,952,130	$77,410,390	-$23,476,448	$43,923	$5,203	$1.21	84
2024 Q1	74,706,106	$175,527,975	+$94,399,818	$57,810	$31,255	$2.35	95
2023 Q4	33,363,531	$63,033,295	-$410,004	$32,886	$3,213	$1.89	76
2023 Q3	35,246,147	$48,263,214	-$4,164,619	$28,359	$3,562	$1.37	82
2023 Q2	36,692,076	$89,136,686	-$29,205,547	$60,993	$49,815	$2.43	91
2023 Q1	40,249,929	$231,250,367	-$1,583,590	$158,400	$1,082,208	$5.76	105
2022 Q4	42,018,768	$375,641,780	-$24,086,836	$701,234	$842,148	$8.94	98
2022 Q3	39,843,943	$566,511,784	+$47,175,226	$1,535,000	$2,164,000	$14.22	93
2022 Q2	34,931,072	$510,109,820	-$6,734,814	$1,115,000	$2,100,000	$14.60	93
2022 Q1	33,013,038	$659,188,374	+$43,093,303	$1,975,000	$1,756,000	$19.97	84
2021 Q4	30,384,210	$531,133,057	+$190,507,506	$2,046,000	$4,233,000	$17.49	77
2021 Q3	19,920,135	$156,120,000	-$14,651,408			$7.84	54
2021 Q2	21,191,849	$218,015,000	+$7,916,893			$10.29	63
2021 Q1	20,351,277	$266,022,000	+$142,412,229			$13.08	50
2020 Q4	8,744,502	$122,857,000	+$6,730,362			$14.05	37
2020 Q3	9,051,029	$107,615,000	+$107,615,173			$11.89	28